In 2025, the China market accounted for USD 29.95 billion.
Our assessment shows the China Infusion Services Market is expected to reach USD 102.07 billion by 2033, achieving a CAGR of 16.6% during the forecast period.
Hospital-centered delivery remains dominant as oncology incidence and biologic reimbursement inclusion under the National Reimbursement Drug List expand infusion volumes nationwide.
The National Health Commission reports continued growth in cancer treatment activity, sustaining strong systemic therapy utilization across tertiary hospitals.
DataCube Research Report (Feb 2026): This analysis uses 2024 as the actual year, 2025 as the estimated year, and calculates CAGR for the 2025-2033 period.
*Research Methodology: This report is based on DataCube’s proprietary 3-stage forecasting model, combining primary research, secondary data triangulation, and expert validation.
[Learn more]